ClinicalTrials.gg
Active, not recruitingNCT06388200liMeliGhTUpdated Jul 31, 2026

A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

A Phase 3 interventional study of Sub-Retinal Administration of OCU400-301 in Retinitis Pigmentosa, sponsored by Ocugen. Active, not recruiting at 17 sites in 2 countries. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Ocugen · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
3 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 119 studies in Retinitis Pigmentosa with a site in United States — 20 open to participants now, 43 under way, 6 of them phase 3. Retinitis Pigmentosa · United States.

Enrollment
7th of 78
140 · median 21
Started
2024
with 5 others
Phase 3
8 of 119
1 open now
Primary completion
2027-02
later than 14 of 41 live
Registered
106th of 119
by date

Among the 119 studies in Retinitis Pigmentosa with a site in United States, this one is the 7th largest by enrollment of the 78 interventional ones that give a count, is one of 6 that started in 2024, is one of 8 in phase 3, reaches primary completion later than 14 of the 41 other live ones, and was the 106th registered.

Retinitis Pigmentosa

281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.

Browse Retinitis Pigmentosa studies →

Open to participants now

20 of the 119 studies in Retinitis Pigmentosa with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Retinitis Pigmentosa studies recruiting now, 38 (76%) set no upper age limit and 6 (12%) stop at 75 or younger; 16 take children under 18; 11 take healthy volunteers.

This study: 3 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 119 studies in Retinitis Pigmentosa with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mutation with a clinical phenotype of RP.

This is a multicenter, assessor blinded and randomized study which will enroll 140 subjects. Study has completed enrollment of all 140 subjects.

Read the detailed description

A total of one hundred and forty (140) RP participants will be enrolled in this study into RHO arm or Gene agnostic arm. RHO arm will only enroll participants with confirmed genetic diagnosis of mutation in RHO gene; whereas Gene Agnostic arm will enroll RP Participants based on clinical diagnosis of RP and a confirmed genetic diagnosis with a gene associated with RP.

Subjects in each arm will be randomized into treatment and control groups with a 2:1 ratio. Subjects in the treatment group will receive a sequential, bilateral sub-retinal injection of OCU400 if both eyes meet inclusion criteria. Control or untreated group subjects will receive OCU400 subretinal injection after completion of 12-month follow-up.

03

Conditions studied

  • Retinitis Pigmentosa

Browse trials for

Keywords

  • Modified Gene therapy
  • Retinitis Pigmentosa
  • RHO
  • RP
  • NR2E3
  • Subretinal Injection
04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females ≥ 3 years of age
  2. Confirmed genetic diagnosis of autosomal dominant RHO mutation with clinical diagnosis of RP
  3. Clinical Diagnosis of Syndromic or Non-Syndromic RP with/without confirmed genetic diagnosis of any other RP associated mutation (except AD-NR2E3)
  4. BCVA ≤ 80 letters and ≥25 letters as measured by an ETDRS chart
  5. Visual field of >5° in any meridian as measured by a III4e isopter or equivalent
  6. Able to perform a Luminance LDNA at certain light intensity at the Screening visit
  7. Presence of photoreceptors as determined by SD-OCT

Exclusion criteria

Exclusion Criteria:

  1. Subject lacks evidence of outer nuclear layer
  2. Previous treatment with a gene-therapy or cell therapy product or treatment with any drug or ocular device within one year.
  3. History of any , corticosteroid related IOP spikes or uncontrolled glaucoma.
  4. Cataract surgery within 3 months. YAG capsulotomy within 1 month. Any other intraocular surgery within 6 months.
  5. Active ocular/intraocular infection, any history of rhegmatogenous retinal detachment or Current retinal detachment or retinal implant.
  6. Breast-feeding, pregnancy, sperm donation or inability to practice strict
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    RHO Arm

    Subjects will receive a sub-retinal injection of OCU400-301 modifier gene therapy product with a concentration of 2.5 x 10\^10 vg/eye

    Genetic: Sub-Retinal Administration of OCU400-301

  • Experimental
    Gene Agnostic Arm

    Subjects will receive a sub-retinal injection of OCU400-301 modifier gene therapy product with a concentration of 2.5 x 10\^10 vg/eye

    Genetic: Sub-Retinal Administration of OCU400-301

  • No intervention
    Control for RHO Arm

    Will not receive any active study intervention

  • No intervention
    Control for Gene Agnostic Arm

    Will not receive any active study intervention

Interventions

  • GeneticSub-Retinal Administration of OCU400-301

    Sub-Retinal Administration of OCU400-301

06

What researchers measure

Primary outcomes

  1. Change in functional vision from baseline to week 52 in pooled analysis when study eyes in treatment group were compared to study eyes in untreated control

    Change in functional vision from baseline to week 52 in pooled analysis from retinitis pigmentosa subjects when study eyes in treatment group were compared to study eyes in untreated control, as measured by the ability of a study participant to navigate through a maze in Luminance Dependent Navigation Assessment (LDNA)

    Time frame: 52 weeks

Secondary outcomes

  1. Change in functional vision from baseline to week 52 in all the treated eyes from RP subjects (study eyes + fellow treated eyes) when compared to all the eyes (study eyes and fellow eyes) in untreated control group

    Change in functional vision from baseline to week 52 in all the treated eyes from RP subjects (study eyes + fellow treated eyes) when compared to all the eyes (study eyes and fellow eyes) in untreated control group, as measured by the ability of a study participant to navigate through a maze in Luminance Dependent Navigation Assessment (LDNA).

    Time frame: 52 weeks

  2. Change from Baseline in visual function in patients with retinitis pigmentosa when treatment group were compared to untreated controls

    Change from Baseline in visual function in patients with retinitis pigmentosa when treatment group were compared to untreated controls in all RP subjects, as assessed by binocular low luminance visual acuity when using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart letter score at Week 52.

    Time frame: 52 weeks

  3. Change from baseline in LDNA Lux-level results in treated subjects when compared to the untreated controls

    Change from baseline in LDNA Lux-level results in all RP subjects in treated subjects when compared to the untreated controls at weeks 12, 24, 36, and 52

    Time frame: 52 weeks

  4. Number of participants with change in visual function in Gene Agnostic Arm as assessed by LLVA letter scores

    Change in LLVA letter scores in Gene Agnostic Arm subjects will be compared to controls

    Time frame: 52 weeks

Other outcomes

  1. Change from baseline in Patients Global Impression of Change (PGIC) score

    Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by: Change from baseline in Patients Global Impression of Change (PGIC) score.

    Time frame: 52 weeks

  2. Change from baseline in Best corrected visual acuity (BCVA) measured by ETDRS

    Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by: Change from baseline in Best corrected visual acuity (BCVA) measured by ETDRS.

    Time frame: 52 weeks

  3. Improvement in Low luminance deficit (LLD) from baseline measured by ETDRS

    Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by: Improvement in Low luminance deficit (LLD) from baseline measured by ETDRS.

    Time frame: 52 weeks

  4. Improvement in mean retinal sensitivity from baseline as measured by static perimetry in the 30-degree

    Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by: Improvement in mean retinal sensitivity from baseline as measured by static perimetry in the 30-degree.

    Time frame: 52 weeks

  5. Change from baseline in hyperfluorescent ring as measured by Wide field-FAF

    Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by: Change from baseline in hyperfluorescent ring as measured by Wide field-FAF.

    Time frame: 52 weeks

  6. Change from baseline in area of RP atrophy in macular region as measured by Wide field-FAF

    Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by: Change from baseline in area of RP atrophy in macular region as measured by Wide field-FAF.

    Time frame: 52 weeks

  7. Change from baseline in hypo autofluorescence assessments in peripheral retina as measured by Wide field-FAF

    Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by: Change from baseline in hypo autofluorescence assessments in peripheral retina as measured by Wide field-FAF.

    Time frame: 52 weeks

  8. Change from baseline in hyper autofluorescence assessments in peripheral retina as measured by Wide field-FAF

    Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by change from baseline in hyper autofluorescence assessments in peripheral retina as measured by Wide field-FAF.

    Time frame: 52 weeks

  9. Changes in the Ellipsoid zone area from baseline as measured by SD-OCT

    Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by changes in Ellipsoid zone area from baseline as measured by SD-OCT.

    Time frame: 52 weeks

  10. Changes in the outer segment length from baseline as measured by SD-OCT

    Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by changes in the outer segment length as measured by SD-OCT.

    Time frame: 52 weeks

  11. Changes in the outer segment volume from baseline as measured by SD-OCT

    Evaluate the efficacy of OCU400 gene therapy in treatment group when compared to untreated controls (in pooled analysis from patients in RHO arm and gene agnostic arm) with Retinitis Pigmentosa through week 52 as indicated by changes in the outer segment volume from baseline as measured by SD-OCT.

    Time frame: 52 weeks

07

Study locations

17 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Feb 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2024
First posted
Apr 29, 2024
StartActual
Jun 18, 2024
Primary completionEst.
Feb 12, 2027
CompletionEst.
Feb 12, 2027
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06388200
Lead sponsor
Ocugen
Responsible party
Sponsor
First posted
Apr 29, 2024
Start date
Jun 18, 2024
Primary completion
Feb 12, 2027 (estimated)
Completion
Feb 12, 2027 (estimated)
Last update
Jul 31, 2026

Study contacts

Jennifer Henrick, RN, MS
study director · Ocugen
Mohamed Genead, MD
study chair · Ocugen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion